Merrimack Pharmaceuticals Company Profile (NASDAQ:MACK)

About Merrimack Pharmaceuticals (NASDAQ:MACK)

Merrimack Pharmaceuticals logoMerrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development. Its advanced program is its therapeutic MM-398, which it markets in the United States under the brand name ONIVYDE. Its other clinical stage product candidates include MM-121, MM-141, MM-310, MM-302 and MM-151. The Company is developing in vitro and in vivo diagnostics for use with each of its oncology therapeutic product candidates. Its in vitro diagnostic agents employ biophysical or biochemical markers of cancer, or biomarkers. Its in vivo diagnostics take the form of imaging agents that may help identify patients likely to benefit from its therapeutic products by measuring deposition of its products in the tumor.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:MACK
  • CUSIP: 59032810
  • Web: www.merrimackpharma.com
Capitalization:
  • Market Cap: $437.01 million
  • Outstanding Shares: 132,427,000
Average Prices:
  • 50 Day Moving Avg: $3.34
  • 200 Day Moving Avg: $3.84
  • 52 Week Range: $2.83 - $7.14
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.52
  • P/E Growth: -1.06
Sales & Book Value:
  • Annual Revenue: $144.27 million
  • Price / Sales: 3.03
  • Book Value: ($2.09) per share
  • Price / Book: -1.58
Profitability:
  • EBIDTA: ($88,040,000.00)
  • Net Margins: -160.00%
  • Return on Assets: -96.01%
Debt:
  • Debt-to-Equity Ratio: -0.96%
  • Current Ratio: 1.02%
  • Quick Ratio: 0.85%
Misc:
  • Average Volume: 2.02 million shs.
  • Beta: 1.92
  • Short Ratio: 13.8
 

Frequently Asked Questions for Merrimack Pharmaceuticals (NASDAQ:MACK)

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

How often does Merrimack Pharmaceuticals pay dividends? What is the dividend yield for Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals announced an annual dividend on Friday, April 7th. Stockholders of record on Wednesday, May 17th will be paid a dividend of $1.06 per share on Friday, May 26th. The ex-dividend date is Tuesday, May 30th. View Merrimack Pharmaceuticals' Dividend History.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.22) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.07) by $0.15. During the same period in the previous year, the business posted ($0.33) EPS. View Merrimack Pharmaceuticals' Earnings History.

Where is Merrimack Pharmaceuticals' stock going? Where will Merrimack Pharmaceuticals' stock price be in 2017?

5 brokers have issued twelve-month target prices for Merrimack Pharmaceuticals' shares. Their forecasts range from $5.00 to $13.00. On average, they expect Merrimack Pharmaceuticals' share price to reach $8.33 in the next twelve months. View Analyst Ratings for Merrimack Pharmaceuticals.

What are analysts saying about Merrimack Pharmaceuticals stock?

Here are some recent quotes from research analysts about Merrimack Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Merrimack reported a wider-than-expected loss in the quarter and generated no revenue as it sold Onivyde to Ipsen. With the sale of Onivyde, the company is back to being a development-stage biopharmaceutical company. Thus, the successful development of the three lead candidates in its pipeline is critical for Merrimack’s growth. Moreover, two of the candidates, MM-121 and MM-141, are still being evaluated in phase II studies. And the third candidate, MM-310 entered phase I study in the first quarter of 2017. Also, shares of the company have underperformed the Zacks categorized Medical Biomed/Genetics industry year to date. However, the cash received from Ipsen will be used to pay down the huge debt and return value to shareholders in the form of dividends." (5/15/2017)
  • 2. JPMorgan Chase & Co. analysts commented, "Our view that 2016 consensus estimates, while achievable, are perhaps not meaningfully beatable (and 2017 needs to moderate incrementally, in our view)."Key pipeline catalysts, while underappreciated, are weighted 2Q17+."Our expectation that R&D prioritization and search for a new CEO could take time (currently no timelines outlined)."A continued financing overhang (~12 months of cash)." (10/7/2016)

Are investors shorting Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals saw a drop in short interest in May. As of May 15th, there was short interest totalling 22,373,586 shares, a drop of 10.3% from the April 28th total of 24,938,481 shares. Based on an average daily volume of 1,791,349 shares, the short-interest ratio is presently 12.5 days. Currently, 18.1% of the shares of the company are short sold.

Who are some of Merrimack Pharmaceuticals' key competitors?

Who owns Merrimack Pharmaceuticals stock?

Merrimack Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (14.80%), Vanguard Group Inc. (7.86%), State Street Corp (5.06%), TIAA CREF Investment Management LLC (4.89%), Teachers Advisors LLC (1.44%) and Geode Capital Management LLC (0.77%). Company insiders that own Merrimack Pharmaceuticals stock include Birgit M Schoeberl, Daryl C Drummond, Edward J Stewart, Michael E Porter, Ulrik B Nielsen, Vivian S Lee, William A Sullivan and William M Mcclements. View Institutional Ownership Trends for Merrimack Pharmaceuticals.

Who sold Merrimack Pharmaceuticals stock? Who is selling Merrimack Pharmaceuticals stock?

Merrimack Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Lagoda Investment Management L.P., Teachers Advisors LLC, Morgan Stanley, AXA, FMR LLC, Alliancebernstein L.P., UBS Group AG and Stoneridge Investment Partners LLC. Company insiders that have sold Merrimack Pharmaceuticals stock in the last year include Birgit M Schoeberl and Daryl C Drummond. View Insider Buying and Selling for Merrimack Pharmaceuticals.

Who bought Merrimack Pharmaceuticals stock? Who is buying Merrimack Pharmaceuticals stock?

Merrimack Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Vanguard Group Inc., Candriam Luxembourg S.C.A., Yakira Capital Management Inc., Credit Suisse AG, Kempner Capital Management Inc., Cornerstone Capital Management Holdings LLC. and Airain ltd. Company insiders that have bought Merrimack Pharmaceuticals stock in the last two years include Michael E Porter, Vivian S Lee and William M Mcclements. View Insider Buying and Selling for Merrimack Pharmaceuticals.

How do I buy Merrimack Pharmaceuticals stock?

Shares of Merrimack Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Merrimack Pharmaceuticals stock cost?

One share of Merrimack Pharmaceuticals stock can currently be purchased for approximately $3.30.

Analyst Ratings

Consensus Ratings for Merrimack Pharmaceuticals (NASDAQ:MACK) (?)
Ratings Breakdown: 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $8.33 (152.53% upside)

Analysts' Ratings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017Cowen and CompanyReiterated RatingMarket PerformLowView Rating Details
1/11/2017Robert W. BairdReiterated RatingNeutral$5.00N/AView Rating Details
11/10/2016JPMorgan Chase & Co.Reiterated RatingHold$7.00N/AView Rating Details
11/10/2016BTIG ResearchReiterated RatingNeutralN/AView Rating Details
8/5/2016Brean CapitalSet Price TargetBuy$16.00 -> $13.00N/AView Rating Details
5/20/2016MizuhoReiterated RatingBuy$13.00N/AView Rating Details
12/30/2015Oppenheimer Holdings Inc.Reiterated RatingBuyN/AView Rating Details
8/11/2015Cantor FitzgeraldReiterated RatingBuy$16.00N/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Earnings by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
Earnings History by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.07)($0.22)$32.16 millionViewN/AView Earnings Details
3/1/2017Q416($0.21)($0.25)$50.44 million$61.20 millionViewListenView Earnings Details
11/9/2016Q316($0.27)($0.23)$41.00 million$28.07 millionViewListenView Earnings Details
8/4/2016Q216($0.33)($0.40)$33.35 million$33.70 millionViewN/AView Earnings Details
5/2/2016Q116($0.38)($0.33)$24.16 million$21.30 millionViewN/AView Earnings Details
2/25/2016Q415($0.41)($0.41)$31.73 million$21.42 millionViewListenView Earnings Details
11/9/2015Q315($0.40)($0.38)$14.04 million$16.44 millionViewN/AView Earnings Details
8/10/2015Q215($0.31)($0.21)$17.57 million$36.60 millionViewListenView Earnings Details
5/7/2015Q1 2015($0.30)($0.32)$14.50 million$14.84 millionViewN/AView Earnings Details
2/26/2015Q4($0.23)($0.09)$25.13 million$33.91 millionViewN/AView Earnings Details
11/10/2014Q3 2014($0.12)($0.27)$61.50 million$28.00 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.32)($0.17)$10.83 million$27.82 millionViewN/AView Earnings Details
5/1/2014Q114($0.31)($0.27)$11.93 million$13.03 millionViewN/AView Earnings Details
2/27/2014($0.29)($0.33)ViewN/AView Earnings Details
11/7/2013($0.34)($0.39)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.28)($0.31)$13.68 million$18.45 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.26)($1.76)$11.77 million$12.58 millionViewN/AView Earnings Details
11/14/2012Q312($1.81)$8.60 million$11.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Merrimack Pharmaceuticals (NASDAQ:MACK)
Current Year EPS Consensus Estimate: $-0.57 EPS
Next Year EPS Consensus Estimate: $-0.73 EPS

Dividends

Dividend History by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/7/2017Annual$1.065/30/20175/17/20175/26/2017
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Insider Ownership Percentage: 11.49%
Institutional Ownership Percentage: 73.14%
Insider Trades by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
Institutional Ownership by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
Insider Trades by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017Daryl C DrummondInsiderSell4,097$3.72$15,240.84View SEC Filing  
7/25/2016Birgit M SchoeberlInsiderSell50,000$5.50$275,000.00View SEC Filing  
3/17/2016Michael E PorterDirectorBuy5,000$7.20$36,000.00View SEC Filing  
3/15/2016Michael E PorterDirectorBuy5,000$7.65$38,250.00View SEC Filing  
3/8/2016Michael E PorterDirectorBuy10,000$7.09$70,900.00View SEC Filing  
3/3/2016Michael E PorterDirectorBuy15,000$6.39$95,850.00View SEC Filing  
3/1/2016Michael E PorterDirectorBuy20,000$6.11$122,200.00View SEC Filing  
2/29/2016Vivian S LeeDirectorBuy35,000$5.50$192,500.00View SEC Filing  
2/29/2016William M McclementsInsiderBuy2,000$5.72$11,440.00View SEC Filing  
1/5/2016Edward J. StewartinsiderSell4,000$8.00$32,000.00View SEC Filing  
12/1/2015Edward J. StewartinsiderSell5,000$9.33$46,650.00View SEC Filing  
11/2/2015Edward J. StewartinsiderSell6,000$9.42$56,520.00View SEC Filing  
10/16/2015Edward J. StewartinsiderSell1,000$10.00$10,000.00View SEC Filing  
10/2/2015Edward J. StewartinsiderSell5,000$8.20$41,000.00View SEC Filing  
9/1/2015Edward J. StewartinsiderSell6,000$9.88$59,280.00View SEC Filing  
8/21/2015Michael E PorterDirectorBuy5,000$9.76$48,800.00View SEC Filing  
8/17/2015Edward J. StewartinsiderSell6,000$10.49$62,940.00View SEC Filing  
8/14/2015Michael E PorterDirectorBuy13,000$10.54$137,020.00View SEC Filing  
7/20/2015Ulrik B NielsenDirectorSell20,000$10.71$214,200.00View SEC Filing  
7/15/2015Edward J StewartInsiderSell6,000$11.84$71,040.00View SEC Filing  
7/15/2015William A SullivanCFOSell15,000$11.85$177,750.00View SEC Filing  
6/19/2015Ulrik B NielsenDirectorSell40,000$12.02$480,800.00View SEC Filing  
6/18/2015Edward J StewartInsiderSell2,000$12.00$24,000.00View SEC Filing  
6/15/2015Edward J StewartInsiderSell6,000$10.67$64,020.00View SEC Filing  
6/15/2015William A SullivanCFOSell15,000$10.65$159,750.00View SEC Filing  
5/19/2015Ulrik B NielsenDirectorSell40,000$13.04$521,600.00View SEC Filing  
5/13/2015Michael E PorterDirectorBuy8,284$11.79$97,668.36View SEC Filing  
4/20/2015Ulrik B NielsenDirectorSell40,000$12.88$515,200.00View SEC Filing  
4/15/2015Edward J StewartSVPSell8,000$12.79$102,320.00View SEC Filing  
4/15/2015William A SullivanCFOSell15,000$12.87$193,050.00View SEC Filing  
4/13/2015Gordon J FehrDirectorSell20,000$13.00$260,000.00View SEC Filing  
3/24/2015Robert J MulroyCEOSell114,368$11.71$1,339,249.28View SEC Filing  
3/23/2015Robert J MulroyCEOSell10,400$11.69$121,576.00View SEC Filing  
3/20/2015Michael E PorterDirectorBuy5,000$11.77$58,850.00View SEC Filing  
3/19/2015Ulrik B NielsenDirectorSell40,000$11.97$478,800.00View SEC Filing  
3/19/2015William A SullivanCFOSell15,000$11.97$179,550.00View SEC Filing  
3/17/2015Birgit M SchoeberlInsiderSell42,234$12.00$506,808.00View SEC Filing  
3/17/2015Edward J StewartSVPSell8,000$11.95$95,600.00View SEC Filing  
3/17/2015Michael E PorterDirectorBuy1,190$11.77$14,006.30View SEC Filing  
3/16/2015Birgit M SchoeberlInsiderSell20,897$12.00$250,764.00View SEC Filing  
3/16/2015Edward J StewartSVPSell6,000$11.93$71,580.00View SEC Filing  
3/11/2015Michael E PorterDirectorBuy5,000$11.33$56,650.00View SEC Filing  
3/2/2015Michael E PorterDirectorBuy5,000$10.93$54,650.00View SEC Filing  
2/23/2015Ulrik B NielsenDirectorSell20,000$10.91$218,200.00View SEC Filing  
2/20/2015Robert J MulroyCEOSell150,000$10.94$1,641,000.00View SEC Filing  
1/15/2015Edward J StewartSVPSell6,000$11.19$67,140.00View SEC Filing  
12/24/2014William A SullivanCFOSell15,000$10.70$160,500.00View SEC Filing  
12/23/2014Vivian S LeeDirectorBuy20,000$10.23$204,600.00View SEC Filing  
12/18/2014Anthony J SinskeyDirectorSell20,000$10.31$206,200.00View SEC Filing  
12/15/2014Edward J StewartSVPSell6,000$10.63$63,780.00View SEC Filing  
12/8/2014Robert J MulroyCEOSell200,000$9.84$1,968,000.00View SEC Filing  
12/2/2014Michael E PorterDirectorBuy8,000$8.71$69,680.00View SEC Filing  
11/21/2014Michael E PorterDirectorBuy11,909$8.87$105,632.83View SEC Filing  
11/18/2014Edward J StewartSVPSell5,000$8.55$42,750.00View SEC Filing  
11/14/2014Michael E PorterDirectorBuy5,000$8.29$41,450.00View SEC Filing  
11/13/2014Gary L CrockerDirectorBuy14,390$8.47$121,883.30View SEC Filing  
11/12/2014Michael E PorterDirectorBuy40,000$8.37$334,800.00View SEC Filing  
10/23/2014Edward J StewartSVPSell3,000$9.05$27,150.00View SEC Filing  
9/30/2014William A SullivanCFOSell105,282$8.61$906,478.02View SEC Filing  
9/29/2014William A SullivanCFOSell64,404$8.40$540,993.60View SEC Filing  
9/24/2014Edward J StewartSVPSell12,000$8.22$98,640.00View SEC Filing  
6/23/2014Gary L CrockerDirectorBuy36,000$6.84$246,240.00View SEC Filing  
5/20/2014Gary CrockerDirectorBuy4,000$6.69$26,760.00View SEC Filing  
5/19/2014Gary CrockerDirectorBuy9,400$6.68$62,792.00View SEC Filing  
5/16/2014Michael PorterDirectorBuy15,000$6.49$97,350.00View SEC Filing  
5/13/2014Anthony SinskeyDirectorBuy5,000$6.74$33,700.00View SEC Filing  
5/8/2014Michael PorterDirectorBuy10,000$6.59$65,900.00View SEC Filing  
5/7/2014Gary CrockerDirectorBuy4,400$6.77$29,788.00View SEC Filing  
5/6/2014Gary CrockerDirectorBuy17,500$6.89$120,575.00View SEC Filing  
5/5/2014Michael PorterDirectorBuy15,000$6.41$96,150.00View SEC Filing  
5/5/2014Robert MulroyCEOBuy5,000$6.31$31,550.00View SEC Filing  
12/17/2013Michael PorterDirectorBuy25,000$4.75$118,750.00View SEC Filing  
12/12/2013William McclementsSVPBuy4,000$4.26$17,040.00View SEC Filing  
12/10/2013Michael PorterDirectorBuy18,000$4.38$78,840.00View SEC Filing  
12/6/2013James QuigleyDirectorBuy39,000$4.70$183,300.00View SEC Filing  
12/4/2013Robert MulroyCEOBuy33,100$4.42$146,302.00View SEC Filing  
12/3/2013Sarah NashDirectorBuy47,500$4.17$198,075.00View SEC Filing  
12/2/2013William McclementsSVPBuy2,000$4.06$8,120.00View SEC Filing  
11/29/2013Anthony SinskeyDirectorBuy3,800$3.92$14,896.00View SEC Filing  
11/27/2013Gary CrockerDirectorBuy207,000$3.72$770,040.00View SEC Filing  
12/14/2012John MendelsohnDirectorBuy5,000$6.63$33,150.00View SEC Filing  
12/13/2012Gary L CrockerDirectorBuy36,500$6.77$247,105.00View SEC Filing  
12/10/2012Michael E PorterDirectorBuy10,000$6.08$60,800.00View SEC Filing  
9/14/2012Gary L CrockerDirectorBuy64,800$8.33$539,784.00View SEC Filing  
8/24/2012James H QuigleyDirectorBuy12,500$7.55$94,375.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Merrimack Pharmaceuticals (NASDAQ:MACK)
Latest Headlines for Merrimack Pharmaceuticals (NASDAQ:MACK)
Source:
DateHeadline
americanbankingnews.com logoMerrimack Pharmaceuticals Inc (MACK) Short Interest Update
www.americanbankingnews.com - May 27 at 7:14 AM
nasdaq.com logoMerrimack Pharmaceuticals, Inc. (MACK) Ex-Dividend Date Scheduled for May 30, 2017 - Nasdaq
www.nasdaq.com - May 26 at 7:13 PM
streetinsider.com logoMerrimack Pharma (MACK) CFO Resigns
www.streetinsider.com - May 26 at 3:36 AM
finance.yahoo.com logoMerrimack Announces Management Change
finance.yahoo.com - May 26 at 3:36 AM
americanbankingnews.com logoMerrimack Pharmaceuticals Inc (mack) to Issue Annual Dividend of $1.06
www.americanbankingnews.com - May 25 at 2:27 PM
americanbankingnews.com logoMerrimack Pharmaceuticals Inc (MACK) Given "Market Perform" Rating at Cowen and Company
www.americanbankingnews.com - May 19 at 10:18 PM
americanbankingnews.com logoMerrimack Pharmaceuticals Inc (MACK) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - May 15 at 12:24 PM
americanbankingnews.com logoInsider Selling: Merrimack Pharmaceuticals Inc (MACK) Insider Sells 4,097 Shares of Stock
www.americanbankingnews.com - May 12 at 8:26 PM
finance.yahoo.com logoEdited Transcript of MACK earnings conference call or presentation 10-May-17 12:30pm GMT
finance.yahoo.com - May 11 at 6:56 PM
finance.yahoo.com logoMerrimack (MACK) Q1 Loss Wider than Expected, Sells Onivyde
finance.yahoo.com - May 11 at 6:56 PM
News IconBRIEF-Merrimack reports Q1 loss per share $0.23
www.businessinsider.com - May 11 at 4:03 AM
prnewswire.com logoMerrimack Reports First Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - May 10 at 5:58 PM
americanbankingnews.com logoMerrimack Pharmaceuticals Inc (MACK) Releases Earnings Results, Misses Expectations By $0.11 EPS
www.americanbankingnews.com - May 10 at 3:52 PM
zacks.com logoMerrimack's (MACK) Reports Wider-than-Expected Q1 Loss
www.zacks.com - May 10 at 12:41 PM
nasdaq.com logoEarnings Reaction History: Merrimack Pharmaceuticals Inc, 36.4% Follow-Through Indicator, 4.2% Sensitive
www.nasdaq.com - May 10 at 12:41 PM
finance.yahoo.com logoMerrimack Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 10 at 12:41 PM
finance.yahoo.com logoInvestor Network: Merrimack Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 10 at 12:41 PM
finance.yahoo.com logoMerrimack's (MACK) Reports Wider-than-Expected Q1 Loss
finance.yahoo.com - May 10 at 12:41 PM
marketbeat.com logoMerrimack reports 1Q loss
marketbeat.com - May 10 at 7:04 AM
americanbankingnews.com logoMerrimack Pharmaceuticals (MACK) Receiving Somewhat Negative Press Coverage, Study Finds
www.americanbankingnews.com - May 3 at 9:48 AM
prnewswire.com logoMerrimack Announces Timing of First Quarter 2017 Investor Conference Call - PR Newswire (press release)
www.prnewswire.com - May 3 at 8:20 AM
finance.yahoo.com logoMerrimack Announces Timing of First Quarter 2017 Investor Conference Call
finance.yahoo.com - May 2 at 7:51 PM
americanbankingnews.com logoMerrimack Pharmaceuticals Inc (MACK) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - May 2 at 2:48 PM
americanbankingnews.com logoMerrimack Pharmaceuticals Inc (MACK) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 2 at 1:56 PM
americanbankingnews.com logoSomewhat Positive Media Coverage Very Unlikely to Impact Merrimack Pharmaceuticals (MACK) Stock Price
www.americanbankingnews.com - April 27 at 11:38 PM
zacks.com logoWhat's in the Cards for Merrimack (MACK) in Q1 Earnings?
www.zacks.com - April 27 at 6:57 PM
americanbankingnews.com logoMerrimack Pharmaceuticals (MACK) Getting Somewhat Favorable Media Coverage, Study Finds
www.americanbankingnews.com - April 23 at 8:55 PM
finance.yahoo.com logoMerrimack Pharmaceuticals, Inc. – Value Analysis (NASDAQ:MACK) : April 19, 2017
finance.yahoo.com - April 19 at 6:30 PM
americanbankingnews.com logoMerrimack Pharmaceuticals (MACK) Receiving Somewhat Favorable Press Coverage, Analysis Finds
www.americanbankingnews.com - April 18 at 8:53 PM
finance.yahoo.com logoMerrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MACK-US : April 18, 2017
finance.yahoo.com - April 18 at 10:33 AM
prnewswire.com logoMerrimack Appoints Daryl Drummond, Ph.D. as Head of Research - PR Newswire (press release)
www.prnewswire.com - April 17 at 10:20 AM
finance.yahoo.com logoMerrimack Appoints Daryl Drummond, Ph.D. as Head of Research
finance.yahoo.com - April 17 at 10:20 AM
seekingalpha.com logoMerrimack: Does Special Dividend In May Present A Buying Opportunity?
seekingalpha.com - April 12 at 7:20 PM
finance.yahoo.com logoMerrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MACK-US : April 4, 2017
finance.yahoo.com - April 7 at 11:02 AM
finance.yahoo.com logoMerrimack Declares $140M Special Dividend in Connection with Recently Completed Asset Sale
finance.yahoo.com - April 7 at 11:02 AM
finance.yahoo.com logoMerrimack Launches as New, Refocused Research & Clinical Development Company with Resources to Advance …
finance.yahoo.com - April 4 at 9:04 AM
reuters.com logoBRIEF-Merrimack completes ONIVYDE sale to Ipsen
www.reuters.com - April 4 at 9:04 AM
us.rd.yahoo.com logoMerrimack Launches as New, Refocused Research & Clinical Development Company with Resources to Advance Prioritized Lead Pipeline Candidates MM-121, MM-141 and MM-310
us.rd.yahoo.com - April 4 at 9:04 AM
bizjournals.com logoIntezyne Technologies Initiates First-In-Human Trials for Topoisomerase-1 Inhibitor IT-141; GRP78 Inhibitor IT-139 to be Featured in AACR Symposium
www.bizjournals.com - April 2 at 10:18 AM
prnewswire.com logoMerrimack Stockholders Approve Sale of ONIVYDE® and Generic Version of DOXIL® to Ipsen for Up to $1.025 Billion - PR Newswire (press release)
www.prnewswire.com - April 1 at 12:00 PM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in Merrimack (MACK) Stock?
finance.yahoo.com - March 31 at 9:47 AM
reuters.com logoBRIEF-Merrimack stockholders approve Onivyde, generic Doxil sale to Ipsen
www.reuters.com - March 30 at 6:43 PM
streetinsider.com logoMerrimack Pharma (MACK) Sale of ONIVYDE® & Generic Version of DOXIL® to Ipsen for Up to $1.025B Approved by Shareholders
www.streetinsider.com - March 30 at 6:43 PM
finance.yahoo.com logoMerrimack Stockholders Approve Sale of ONIVYDE® and Generic Version of DOXIL® to Ipsen for Up to $1.025 Billion
finance.yahoo.com - March 30 at 6:43 PM
finance.yahoo.com logo12:02 pm Merrimack Pharma stockholders vote to approve the asset sale of ONIVYDE and the genereic verison of DOXIL to Ipsen S.A. (IPSEY) for up to $1.025 bln
finance.yahoo.com - March 30 at 6:43 PM
biz.yahoo.com logoMERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - March 30 at 6:43 PM
americanbankingnews.com logoMerrimack Pharmaceuticals Inc (MACK) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 30 at 1:22 PM
finance.yahoo.com logoMerrimack to Present at the 2017 American Association for Cancer Research Annual Meeting
finance.yahoo.com - March 27 at 10:32 AM
americanbankingnews.com logoMerrimack Pharmaceuticals Inc (MACK) Short Interest Down 8.7% in March
www.americanbankingnews.com - March 27 at 7:04 AM
prnewswire.com logoMerrimack Initiates Phase 1 Study of MM-310 in Solid Tumors - PR Newswire (press release)
www.prnewswire.com - March 25 at 9:22 AM

Social

Chart

Merrimack Pharmaceuticals (MACK) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff